Skip to main content
TipRanks
Go Ultimate75% OFF

OrganoClick AB (ORGC) AI Stock Analysis

0 Followers
SE:ORGC

OrganoClick AB

(Nasdaq OMX AB:ORGC)

Select Model
Rating:46Neutral
Price Target:SEK 0.40â–¼(-8.62% Downside)
Action:reiterated
Date:11/13/26

The score is held down primarily by weak financial performance (declining revenue, compressed margins, and continued losses) and an earnings-negative valuation profile (negative P/E with no dividend yield provided). Technical indicators are a partial offset, showing improving near-term momentum versus key short- and medium-term moving averages, but the longer-term trend remains challenged.

Positive Factors
Proprietary green-chemistry platformThe company’s proprietary bio-based chemistry addresses multiple material-treatment needs, including water repellency, flame retardancy, and durability. This provides a platform for branded products and industrial solutions while aligning its offering with the structural shift toward less fossil-based and hazardous inputs.
Negative Factors
Revenue contractionMeaningful revenue contraction indicates weaker demand, customer activity, or business mix and reduces the scale available to absorb fixed costs. If the decline persists, it can limit investment capacity, weaken operating leverage, and make a return to profitability more difficult over the next several quarters.

OrganoClick AB (ORGC) vs. iShares MSCI Sweden ETF (EWD)

-100%-80%-60%-40%-20%0%20%SE:ORGC-74.51%EWD+15.64%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 80.80M
Dividend Yield
―
Average Volume (3M)
229.61K
Price to Earnings (P/E)
-1.7
Beta (1Y)
0.90
Revenue Growth
-27.65%
EPS Growth
3.02%
Country
Sweden
Employees
39
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

OrganoClick AB Business Overview & Revenue Model

Company Description

OrganoClick AB (publ), a technology firm based in Täby, Sweden, was established in 2006. The company specializes in the development, production, and sale of innovative fiber-based materials and chemicals for applications spanning wood treatment, tech...

OrganoClick AB Financial Statement Overview

Summary

Financial performance is pressured: TTM revenue is down ~12%, gross margin has compressed to the mid-teens (vs ~24–25% in 2023–2024), and the company remains loss-making with negative operating profit and a large net loss. Balance sheet leverage has improved versus the 2025 stress point but is still elevated given ongoing losses. Cash flow is the bright spot with slightly positive TTM operating cash flow and near-breakeven (still negative) free cash flow, though sustainability is not yet proven.

Income Statement

24Negative

Balance Sheet

38Negative

Cash Flow

33Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue79.04M106.19M127.23M145.87M115.05M110.06M
Gross Profit11.88M14.86M31.84M35.39M12.94M18.51M
EBITDA-8.77M-12.80M5.71M5.95M-21.19M-12.92M
Net Income-30.16M-36.37M-17.97M-15.77M-41.62M-31.03M
Balance Sheet
Total Assets126.08M135.22M126.98M150.75M162.86M188.39M
Cash, Cash Equivalents and Short-Term Investments1.26M2.68M538.00K10.74M15.20M34.25M
Total Debt58.83M77.78M51.67M62.39M61.68M53.54M
Total Liabilities84.76M114.81M89.15M97.34M95.30M80.66M
Stockholders Equity37.47M15.18M28.98M44.58M58.78M100.33M
Cash Flow
Free Cash Flow-306.00K-10.51M-5.51M-8.08M-35.35M-52.34M
Operating Cash Flow1.35M-8.29M3.60M533.00K-21.22M-37.69M
Investing Cash Flow-9.84M-10.99M-9.11M-8.61M-7.45M-14.65M
Financing Cash Flow4.42M21.42M-4.69M3.60M9.63M54.56M

OrganoClick AB Technical Analysis

Technical Analysis SentimentPositive
Last Price0.44

Price Trends

50DMA0.32Positive
100DMA0.37Positive
200DMA0.68Negative

Market Momentum

MACD0.04Positive
RSI56.96Neutral
STOCH28.15Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORGC, the sentiment is Positive. The current price of 0.44 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.32, and below the 200-day MA of 0.68, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 56.96 is Neutral, neither overbought nor oversold. The STOCH value of 28.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ORGC.

OrganoClick AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

SE:ORGC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:PCATSE:PCAT70OutperformSEK 19.18M5.13――-17.14%88.76%
SE:HPOL.BSE:HPOL.B68NeutralSEK 32.77B18.1212.33%4.41%-0.82%-7.46%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
SE:ORGCSE:ORGC46NeutralSEK 80.80M-1.70-156.22%―-27.65%3.02%
SE:POLYGSE:POLYG41NeutralSEK 97.16M-22.30-1.52%―-18.26%35.77%
SE:NEXAMSE:NEXAM40UnderperformSEK 258.28M-12.35-9.37%―-4.57%-15.20%
SE:AEROSE:AERO38UnderperformSEK 23.45M-0.53-87.92%―-11.55%60.56%

* Basic Materials Sector Average

Performance Comparison

-50%0%50%100%SE:ORGCSE:HPOL.BSE:NEXAMSE:AEROSE:POLYGSE:PCATDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ORGC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ORGCOrganoClick AB0.44-1.27-74.27%
SE:HPOL.BHexpol AB95.1519.2425.34%
SE:NEXAMNexam Chemical Holding AB2.52-0.49-16.28%
SE:AEROSvenska Aerogel Holding AB0.44-0.94-68.12%
SE:POLYGPolygiene AB2.66-5.64-67.95%
SE:PCATPhotocat A/S3.20-0.60-15.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026